IL2 and type 1 diabetes mellitus: Next, we carried out long-term T1D prevention studies in NOD.Foxp3EGFP mice, that were, starting at 5-6 weeks-of-age, either left untreated or were treated until 35 weeks-of-age with tetramers only, IL-2:mAb complexes only, or one cycle of the combined optimized treatment followed by either the combined simple treatment or the combined intensive treatment (Supplementary Fig. 7).